U.S. stock night trading volatility: Oncolytics Biotech rose nearly 10% in after-hours trading, boosted by FDA key study protocol enhancing market confidence

U.S. Stock Night Market Movements Oncolytics Biotech rose 9.95% in the night market. Based on recent key news: On April 27, Oncolytics Biotech announced an agreement with the U.S. Food and Drug Administration (FDA) on the design of a key clinical study aimed at supporting the approval of pelareorep for patients with unresectable metastatic anal squamous cell carcinoma. Following this announcement, the company's stock price rose. Source: Reuters On April 27, Oncolytics Biotech disclosed its agreement with the FDA in an SEC filing, further boosting market confidence in its new drug development, leading to a rise in stock price. Source: Reuters On April 27, Oncolytics Biotech released a related announcement via GlobeNewswire, emphasizing the FDA's clear guidance and efficient approval pathway, further boosting investor confidence. Source: Public Technologies The biotech industry has recently been significantly affected by FDA policies. Stocks with High Trading Volume in the Industry Compass Therapeutics had a trading volume of $118,000. Based on recent key news: On April 27, Compass Therapeutics' cancer treatment improved progression-free survival in recent trials but did not meet the secondary endpoint for overall survival. The stock price fell 23% to $3.85 in pre-market trading. Due to a high crossover rate, the trial data is difficult to interpret. Source: WSJ On April 27, LifeSci Capital analyst Charles Zhu maintained a buy rating on Compass Therapeutics with a target price of $6. The consensus rating among analysts is strong buy, with an average target price of $12.43. Source: TipRanks On April 28, Canaccord Genuity lowered the target price for Compass Therapeutics from $13 to $7. Source: MarketBeat The biopharmaceutical industry faces regulatory uncertainties. Intellia Therapeutics rose 1.44% in the night market. Based on recent key news: On April 27, Intellia Therapeutics announced that its experimental therapy achieved its primary goal in late-stage studies. The therapy, lonvoguran ziclumeran, aims to treat hereditary angioedema, and in a trial of 80 patients, a single infusion therapy reduced the frequency of attacks by 87% within six months. This news drove the stock price up. On April 27, Intellia Therapeutics initiated a rolling submission to the FDA for lonvoguran ziclumeran, aiming for U.S. market approval in 2027 The news further enhances market confidence in the company's future development. On April 28, Intellia Therapeutics announced the launch of a $150 million public offering, with all shares to be sold by the company. This move aims to provide funding support for the company's future development, and the market reacted positively. The gene editing therapy market has broad prospects, with significant capital inflow. Absci fell 1.23% in after-hours trading. There has been no significant news recently; trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news